- Type / Class
- Equity / Common Stock
- Shares outstanding
- 159,231,812
- Total 13F shares
- 115,545,961
- Share change
- -1,210,183
- Total reported value
- $696,530,447
- Put/Call ratio
- 26%
- Price per share
- $6.03
- Number of holders
- 217
- Value change
- -$6,968,225
- Number of buys
- 87
- Number of sells
- 107
Quarterly Holders Quick Answers
What is CUSIP 92764N102?
CUSIP 92764N102 identifies VIR - Vir Biotechnology, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92764N102:
Top shareholders of VIR - Vir Biotechnology, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD |
13F
13D/G
|
Company · SB Investment Advisers (UK) Limited |
9.4%
from 13D/G
|
16,684,041
|
$95,265,874 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
11%
|
14,826,039
|
$93,255,785 | $0 | 31 Mar 2025 | |
| SVF Endurance (Cayman) Ltd |
3/4/5
|
10%+ Owner |
8.6%
|
13,728,924
|
$82,134,660 | -$17,847,707 | 01 Dec 2025 | |
| ARCH Venture Management, LLC |
13F
|
Company |
8.1%
|
12,916,663
|
$73,754,146 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8%
|
12,799,381
|
$73,084,465 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.3%
|
5,241,293
|
$29,927,783 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
2.3%
|
3,637,130
|
$20,768,011 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.9%
|
2,978,871
|
$17,008,661 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.7%
|
2,689,118
|
$15,354,867 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.5%
|
2,380,715
|
$13,593,883 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
2,246,222
|
$12,828,245 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.96%
|
1,526,265
|
$8,714,973 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.96%
|
1,521,802
|
$8,689,490 | — | 30 Sep 2025 | |
| George A. Scangos |
3/4/5
|
Director |
—
mixed-class rows
|
894,169
mixed-class rows
|
$8,326,163 | — | 24 Feb 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.88%
|
1,396,504
|
$7,974,038 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.73%
|
1,167,100
|
$6,664,141 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
1,142,879
|
$6,525,839 | — | 30 Sep 2025 | |
| Robert Nelsen |
3/4/5
|
Director |
—
mixed-class rows
|
634,041
mixed-class rows
|
$5,869,727 | — | 30 May 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.57%
|
911,882
|
$5,206,846 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
907,126
|
$5,179,689 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.5%
|
799,034
|
$4,562,484 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.45%
|
716,388
|
$4,090,000 | — | 30 Sep 2025 | |
| NORDEA INVESTMENT MANAGEMENT AB |
13F
|
Company |
0.45%
|
714,561
|
$3,930,086 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.41%
|
649,300
|
$3,707,503 | — | 30 Sep 2025 | |
| Clarius Group, LLC |
13F
|
Company |
0.39%
|
619,312
|
$3,536,272 | — | 30 Sep 2025 | |
| Robert J. More |
3/4/5
|
Director |
—
mixed-class rows
|
566,573
mixed-class rows
|
$3,410,503 | — | 09 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.37%
|
593,374
|
$3,388,167 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.35%
|
557,018
|
$3,180,574 | — | 30 Sep 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.35%
|
554,981
|
$3,168,942 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.34%
|
542,539
|
$3,097,898 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
516,628
|
$2,949,946 | — | 30 Sep 2025 | |
| Alta Partners Management Company, L.P. |
13F
|
Company |
0.32%
|
509,917
|
$2,911,626 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.32%
|
504,000
|
$2,877,840 | — | 30 Sep 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.3%
|
478,343
|
$2,731,339 | — | 30 Sep 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.29%
|
455,700
|
$2,602,048 | — | 30 Sep 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.29%
|
456,292
|
$2,568,924 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.28%
|
449,518
|
$2,566,747 | — | 30 Sep 2025 | |
| Phillip Pang |
3/4/5
|
EVP & Chief Medical Officer |
—
class O/S missing
|
250,111
|
$2,512,515 | — | 22 Feb 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.26%
|
417,956
|
$2,386,529 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.26%
|
410,406
|
$2,343,419 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.25%
|
400,983
|
$2,289,612 | — | 30 Sep 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.23%
|
367,264
|
$2,097,077 | — | 30 Sep 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.23%
|
360,417
|
$2,057,981 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.2%
|
323,525
|
$1,847,328 | — | 30 Sep 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.19%
|
296,017
|
$1,690,257 | — | 30 Sep 2025 | |
| Allianz Asset Management GmbH |
13F
|
Company |
0.18%
|
284,227
|
$1,622,936 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
277,703
|
$1,585,684 | — | 30 Sep 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.17%
|
277,315
|
$1,583,469 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.17%
|
272,170
|
$1,554,091 | — | 30 Sep 2025 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.17%
|
263,897
|
$1,506,852 | — | 30 Sep 2025 |
Institutional Holders of Vir Biotechnology, Inc. - Common Stock (VIR) as of Q4 2025
As of 31 Dec 2025,
Vir Biotechnology, Inc. - Common Stock (VIR) was held by
217 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,545,961 shares.
The largest 10 holders included
BlackRock, Inc., SB INVESTMENT ADVISERS (UK) LTD, ARCH Venture Management, LLC, VANGUARD GROUP INC, GSK plc, STATE STREET CORP, FMR LLC, MORGAN STANLEY, DIMENSIONAL FUND ADVISORS LP, and ORBIMED ADVISORS LLC.
This page lists
217
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
209
Q4 2025 holders
217
Holder diff
8
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.